dRAvite-LTENCT07620392
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 10 → 17 locations
- Minor Study sites: 10 to 12
- Notable Eligibility criteria expanded, about 7 words
- Study sites: 9 to 10
- Secondary endpoints: details revised at 1 of 13 entries
- Minor Trial sites expanded: 6 → 9 locationsv4
- Minor Trial sites expanded: 1 → 6 locationsv3
- Notable Primary and study completion pushed from Jun 5, 2032 to Jul 8, 2033
- Recruitment opened
- Study sites: 0 to 1
- Start date changed from estimate of Jun 5, 2026 to Jun 3, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of Participants With Adverse Events (AEs)
Timeframe: From Baseline up to 6 years
Secondary (13)
Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%), 50% or 70% Improvement (ACR20/ACR50/ACR70)
Change from baseline in Individual Components of ACR
Change From Baseline in Disease Activity Score-28 for Rheumatoid Arthritis With C-Reactive Protein (DAS28-CRP)
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28-CRP Score
Percentage of Participants LDA Achieving Based on Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation (DAS28-ESR) Score
Show 8 moreShow less
Percentage of Participants Achieving LDA Based Clinical Disease Activity Index (CDAI) Score
Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28-CRP Score
Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28-ESR Score
Percentage of Participants Achieving Clinical Remission (CR) Based on CDAI Score
Percentage of Participants Achieving Clinical Remission (CR) Based on SDAI Score
Serum Concentration of Afimkibart
Percentage of Participants with Anti-Drug Antibodies (ADAs) to Afimkibart at Baseline and with ADAs to Afimkibart During the Study
Percentage of Participants with Neutralizing Antibody (NAb) to Afimkibart
Arms and interventions
Afimkibart Group IExperimental
Participants will recieve Afimkibart as subcutaneous (SC) injection.
Afimkibart Group IIExperimental
Participants will receive Afimkibart as SC injection.
Drugs: Afimkibart
Sites
17 sites in 5 countries
Poland 6, United States 5, Brazil 3, Argentina 2, Spain 1